Ginkgo Bioworks Holdings, Inc.
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
DNA$12.37+9.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share data)
| As of March 31, | As of December 31, | |
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $312,420 | $561,572 |
| Marketable securities | 204,502 | — |
| Accounts receivable, net | 26,293 | 21,857 |
| Accounts receivable - related parties | 877 | 586 |
| Prepaid expenses and other current assets | 20,442 | 18,729 |
| Total current assets | 564,534 | 602,744 |
| Property, plant and equipment, net | 197,828 | 203,720 |
| Operating lease right-of-use assets | 383,394 | 394,435 |
| Investments | 32,173 | 48,704 |
| Intangible assets, net | 68,756 | 72,510 |
| Other non-current assets | 46,778 | 55,336 |
| Total assets | $1,293,463 | $1,377,449 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $11,267 | $14,169 |
| Deferred revenue (includes $391 and $795 from related parties) | 33,653 | 27,710 |
| Accrued expenses and other current liabilities | 70,747 | 65,387 |
| Total current liabilities | 115,667 | 107,266 |
| Non-current liabilities: | ||
| Deferred revenue, net of current portion (includes $64,786 and $72,260 from related parties) | 80,378 | 98,783 |
| Operating lease liabilities, non-current | 434,561 | 438,766 |
| Other non-current liabilities | 15,430 | 16,576 |
| Total liabilities | 646,036 | 661,391 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 200,000,000 shares authorized; none issued | — | — |
| Common stock, $0.0001 par value (Note 8) | 5 | 5 |
| Additional paid-in capital | 6,576,786 | 6,555,416 |
| Accumulated deficit | (5,928,514) | (5,837,557) |
| Accumulated other comprehensive loss | (850) | (1,806) |
| Total stockholders’ equity | 647,427 | 716,058 |
| Total liabilities and stockholders’ equity | $1,293,463 | $1,377,449 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.